Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ErbB Receptors”

930 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 930 results

Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Testing effectiveness (Phase 2)UnknownNCT01732276
What this trial is testing

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Jiangmen Central Hospital 50
Large-scale testing (Phase 3)Looking for participantsNCT06340568
What this trial is testing

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Who this might be right for
Endometrial Cancer
BioNTech SE 480
Testing effectiveness (Phase 2)UnknownNCT02967497
What this trial is testing

Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type

Who this might be right for
Epithelial Growth Factor Receptor Negative Non-small Cell Lung Cancer
Taipei Veterans General Hospital, Taiwan 56
Early research (Phase 1)Ended earlyNCT03255083
What this trial is testing

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 13
Testing effectiveness (Phase 2)Looking for participantsNCT07326566
What this trial is testing

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Who this might be right for
Glioblastoma (GBM)Newly Diagnosed GlioblastomaGBM+4 more
Black Diamond Therapeutics, Inc. 162
Testing effectiveness (Phase 2)Ended earlyNCT02770014
What this trial is testing

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Who this might be right for
Epidermal Growth Factor ReceptorNon-Small Cell Lung Cancer
Dana-Farber Cancer Institute 43
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06545695
What this trial is testing

Epidermal Growth Factor Receptor Inhibition for Keratinopathies

Who this might be right for
Epidermolytic IchthyosisPalmoplantar KeratodermaPachyonychia Congenita
Northwestern University 44
Early research (Phase 1)Study completedNCT02476539
What this trial is testing

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd 28
Large-scale testing (Phase 3)Ended earlyNCT03419403
What this trial is testing

UNITE Study: Understanding New Interventions With GBM ThErapy

Who this might be right for
Glioblastoma Multiforme
AbbVie 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Very early researchNot Yet RecruitingNCT07498595
What this trial is testing

TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

Who this might be right for
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Tianjin Medical University General Hospital 50
Large-scale testing (Phase 3)UnknownNCT03008109
What this trial is testing

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Who this might be right for
Advanced CancerLung Cancer, Nonsmall Cell
Zaiwen Fan 80
Not applicableUnknownNCT02661009
What this trial is testing

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Who this might be right for
Non Small Cell Lung CancerEGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation
GenoSaber 1,000
Early research (Phase 1)Study completedNCT01526473
What this trial is testing

A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901

Who this might be right for
HER2+ Cancer
H. Kim Lyerly 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT05593094
What this trial is testing

Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsHER2-positive Breast Cancer
Hoffmann-La Roche 210
Large-scale testing (Phase 3)Ended earlyNCT01641939
What this trial is testing

Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 415
Not applicableApproved For MarketingNCT04535557
What this trial is testing

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Millennium Pharmaceuticals, Inc.
Next Page